Real-World Outcomes in Diabetic Macular Edema for the 0.2 μg/Day Fluocinolone Acetonide Implant: Case Series from the Midlands, UK
Bushra Mushtaq,1 Ajay Bhatnagar,2 Helen Palmer3 1Birmingham Midland Eye Centre, City Hospital SWBH NHS Trust, Birmingham, UK; 2Department of Ophthalmology, New Cross Hospital, The Royal Wolverhampton NHS Trust, Wolverhampton, UK; 3Ophthalmology Department, Queen Elizabeth Hospital Birmingham, Univer...
Saved in:
Main Authors: | Mushtaq B, Bhatnagar A, Palmer H |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/a953b7d4d1554637892f67b5c9855e19 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN®) and Follow-Up Considerations/Recommendations
by: Adán A, et al.
Published: (2020) -
Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
by: Saedon H, et al.
Published: (2017) -
Update on corticosteroids for diabetic macular edema
by: Schwartz SG, et al.
Published: (2016) -
Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study
by: Massin P, et al.
Published: (2016) -
Effectiveness of 190 μg Fluocinolone Acetonide and 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis
by: Zarranz-Ventura J, et al.
Published: (2020)